On August 1, Wuhan YZY Medical Science and Technology Co., Ltd. (hereinafter referred to as “YZY Med”) signed a strategic cooperation agreement with Hubei C&C Biopharmaceutical Co. Ltd. (hereinafter referred to as “C&C”).Both parties announced an in-depth cooperation in the field of cardiovascular disease treatment, and will make full use of respective cardiovascular technology advantages to jointly promote the application of Policosanol tablets (non-statin) and statin-metabolic gene testing kits (SLCO1B1 & ApoE), thus opening a new chapter of cardiovascular precision medicine!
Mr. Liu Xiaogang, General Manager of YZY Med and Dr. Cai Lei, Vice Chairman of C&C, witnessed the important moment of strategic cooperation as signatories.
Pictured from left to right: Mr. Liu Xiaogang, Dr. Cai Lei
GM Mr Liu said, “The company always attaches great importance to the cooperation with pharmaceutical companies and has been providing pharmacogenomic testing solutions to domestic and overseas customers for a long time. We believe that this strategic cooperation will further accelerate the efficiency of cardiovascular drug development and clinical application, and provide patients with more accurate personalized medical services and better treatment options. As a molecular diagnostic enterprise in the field of pharmacogenomics for many years, YZY Med has always adhered to the corporate mission of “The Right Drug for The Right Patient”, and strives to become a leading enterprise in the field of personalized medicine and build an excellent platform for realizing self-worth and contributing back to the society.”
C&C
Vice Chairman Dr. Cai Lei said, “Adhering to the spirit of ‘cooperation and innovation’ and ‘pursuit of excellence’, C&C is committed to helping patients to improve their health through innovative medicines and precision medical technologies. Policosanol Tablet has the effect of lowering cholesterol, anti-platelet aggregation, improving energy and physical endurance, with high safety, without affecting the liver and kidney function, it is a very good drug for the treatment of hyperlipidemia and the prevention of cardiovascular diseases. It is regarded as “vascular scavenger” by clinical experts. C&C has always insisted on being driven by scientific and technological innovation, and is committed to maintaining a leading position in niche fields and continuously improving the safety and effectiveness of its products, and expects that this in-depth strategic cooperation between the two sides will contribute to the advancement of medicine and human health.”
Signing Ceremony Photo Aug 1, 2024
The signing of this contract will build a more solid bridge for both parties to cooperate in the medical applications both at home and abroad, it symbolizes that both parties determines to jointly promote the further development of cardiovascular disease diagnosis and treatment, combining cardiovascular therapeutic drugs with genetic testing of medication!
